Person:
Chatterjee, Sampurna

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Chatterjee

First Name

Sampurna

Name

Chatterjee, Sampurna
Author's Publications: search.filters.isAuthorOfPublication.cade6c6f-f745-4363-a4b7-a55b9bc68076

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Non-Invasive Monitoring of Chronic Liver Disease via Near-Infrared and Shortwave-Infrared Imaging of Endogenous Lipofuscin
    (Springer Science and Business Media LLC, 2020-08) Saif, Mari; Kwanten, Wilhelmus J.; Carr, Jessica A.; Chen, Ivy X.; Posada, Jessica; Srivastava, Amitabh; Zhang, Juanye; Zheng, Yi; Pinter, Matthias; Chatterjee, Sampurna; Softic, Samir; Kahn, C.; van Leyen, Klaus; Bruns, Oliver T.; Jain, Rakesh; Bawendi, Moungi G.
    Monitoring the progression of non-alcoholic fatty liver disease is hindered by a lack of suitable non-invasive imaging methods. Here, we show that the endogenous pigment lipofuscin displays strong near-infrared and shortwave-infrared fluorescence when excited at 808 nm, enabling label-free imaging of liver injury in mice and the discrimination of pathological processes from normal liver processes with high specificity and sensitivity. We also show that the near-infrared and shortwave-infrared fluorescence of lipofuscin can be used to monitor the progression and regression of liver necroinflammation and fibrosis in mouse models of non-alcoholic fatty liver disease and advanced fibrosis, as well as to detect non-alcoholic steatohepatitis and cirrhosis in biopsied samples of human liver tissue.
  • Thumbnail Image
    Publication
    Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
    (Impact Journals LLC, 2015) Schöttle, Jakob; Chatterjee, Sampurna; Volz, Caroline; Siobal, Maike; Florin, Alexandra; Rokitta, Dennis; Hinze, Yvonne; Dietlein, Felix; Plenker, Dennis; König, Katharina; Albus, Kerstin; Heuckmann, Johannes M.; Rauh, Daniel; Franz, Thomas; Neumaier, Bernd; Fuhr, Uwe; Heukamp, Lukas C.; Ullrich, Roland T.
    Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. We found that intermittent high-dose treatment with erlotinib induced apoptosis more potently and improved tumor shrinkage significantly than the established low doses. In mice carrying EGFR-mutant xenografts intermittent high-dose treatment (200 mg/kg every other day) was tolerable and prolonged progression-free survival and reduced the frequency of acquired resistance. Intermittent EGFR-targeted high-dose schedules induce more profound as well as sustained target inhibition and may afford enhanced therapeutic efficacy.